News

Astra Zeneca ends AZD2820 study
Enlarge image

BusinessSwedenUK

Astra Zeneca ends AZD2820 study

11.09.2012 - Swedish-British pharma Astra Zeneca has stopped the development of one obesity drug but promises to back partner Palatin with the other candidates.

US company Palatin Technologies, Inc. (Cranbury) experienced a setback for one of its developed drugs in June this year when its partner AstraZeneca PLC from Europe paused a Phase I clinical trial after a serious adverse event. Now, the Swedish-British pharma giant decided, after a thorough review, to end the development of this drug completely. However, Palatin also announced that AstraZeneca remains committed to the collaboration programme at large to discover, develop and commercialise compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The ditched clinical candidate called AZD2820 is a subcutaneously-administered peptide that partially agonises the melanocortin-4 receptor. Phase I clinical trials as a single-agent therapy for the treatment of obesity started in the first half of 2011 after AstraZeneca had selected the drug from the collaborative research programme with Palatin Technologies. The single centre study was expected to enrol 90 subjects with a body mass index between 30 and 35 in a randomised, single-blind, placebo-controlled, Phase I trial in healthy male volunteers. After 11 subjects had completed their dosing regimen, the trial was halted by the Safety Review Committee because it suspected that one subject may have had an allergic reaction following his first dose. The volunteer fully recovered but the review by AstraZeneca said that it cannot be excluded that the adverse reactiom was linked to AZD2820. The company however also stated, that it is unlikely that this event was related to melanocortin receptor activation as a mode of action.

http://www.european-biotechnology-news.com/news/news/2012-03/astra-zeneca-ends-azd2820-study.html

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%
  • ADDEX3.19 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014